Almirall, proud sponsor at the next EADV Congress 2026, reinforcing our commitment to Medical Dermatology. This year the congress will be hosted in the city of Vienna (Austria) from 30th September to 3rd October 2026.

Almirall, proud sponsor at the next EADV Congress 2026, reinforcing our commitment to Medical Dermatology.

This year the congress will be hosted in the city of Vienna (Austria) from 30th September to 3rd October 2026.

Our scientific sessions

A range of Scientific Sessions presenting the latest evidence-based data at the EADV Congress 2026. Almirall sessions will run on Thursday 1st and Friday 2nd October. Don’t miss our AD HUB and two inspiring Symposia with world leading panellists, and keep on building the future of medical dermatology with Almirall.

AD HUB

Thursday,

1 October

From 9:15

to 10:00 CEST

HUB 2.07
HUB 2,
-2.41 /
-2.42, Level -2

Looking into the face of AD: tackling clinical cases in moderate-to-severe atopic dermatitis with face and neck involvement including lebrikizumab

Chair

Prof. Christian Vestergaard

Assoc. Prof. Marie Jachiet

9:15

Welcome & introduction

Prof. Christian Vestergaard

9:20

The wish for urgent relief, and stable response in the visible areas and beyond*

Prof. Christian Vestergaard and Ass. Prof. Marie Jachiet

9:35

Maintaining long-term sustained response in AD including challenging areas*

Prof. Christian Vestergaard and Ass. Prof. Marie Jachiet

9:55

Q&A and closing

Prof. Christian Vestergaard and Ass. Prof. Marie Jachiet

* Including discussions of cases on face & neck AD.

Why attend

Join us for an interactive discussion focused on moderate-to-severe atopic dermatitis with face and neck involvement, where clinical complexity often meets high patient burden. Through real-life cases and expert exchange, explore practical considerations in recognition, assessment, and management, and gain valuable insights into how treatment strategies with advanced systemic therapies including lebrikizumab may be applied in patients with challenging visible disease.

AD, atopic dermatitis
▼ EBGLYSS® is approved by EMA and authorised for commercialisation in a number of key markets including Germany, Spain and the United Kingdom. Access EBGLYSS® full SmPC clicking here. Click here for lebrikizumab SmPC. UK and Irish healthcare professionals, click here for UK/IE prescribing information and adverse event reporting instructions. These sessions are organized and funded by Almirall S.A. Almirall product will be discussed. Almirall event, booth and website are intended for healthcare professionals registered at the Congress.

Symposium on psoriasis

Thursday,

1 October

From 17:45

to 18:45 CEST

SAT 11.04

Hall N, Level 1

Redefining treatment success in psoriasis: moving beyond PASI to sustained disease control

Chair

Prof. Ulrich Mrowietz

Prof. Matthias Augustin

Prof. Anna López-Ferrer

Prof. Paolo 
Gisondi

17:45

Redefining treatment success through patient-centered care

Prof. Ulrich Mrowietz

17:55

How to integrate patient perspectives into treatment decisions:
insights from 
the POSITIVE study

Prof. Matthias Augustin

18:10

Where it matters most: managing psoriasis in high-impact areas and ageing populations

Prof. Anna López-Ferrer

18:25

Achieving sustained disease control in complex patients through tailored treatment with tildrakizumab

Prof. Paolo Gisondi

18:40

Q&A and closing

Prof. Ulrich Mrowietz

Prof. Matthias Augustin

Prof. Anna López-Ferrer

Prof. Paolo Gisondi

Why attend

This symposium highlights a value-based, patient-centred approach to psoriasis management, moving beyond traditional metrics to focus on sustained disease control, quality of life, and patient-reported outcomes. Attendees will gain practical strategies to integrate functional impairment and psychological burden into routine clinical decision-making. It provides real-world, evidence-based guidance on achieving durable responses, treatment persistence, and long-term safety in chronic disease management. Emphasis is placed on tailoring treatment according to individual patient characteristics, enabling a personalized approach.

PASI, Psoriasis Area Severity Index. 
These sessions are organized and funded by Almirall S.A. Almirall product will be discussed. Almirall event, booth and website are intended for healthcare professionals registered at the Congress.

Symposium on atopic dermatitis

Friday,
2 October

From 13:00

to 14:00 CEST

SAT 5.06

Hall F2, Level 0

The many faces of AD – spotlight on visible burden, deep response, and simplicity in everyday care with lebrikizumab

Chair

Dr. Christine Bangert

Prof. Diamant Thaçi

Dr. Constanza Riquelme

13:00

Welcome & introduction

Dr. Christine Bangert

13:05

Facing the visible burden: addressing the pathophysiology and introducing new clinical evidence for face & neck atopic dermatitis

Dr. Christine Bangert

13:25

Rethinking AD control: stability and deep response across body regions in AD

Prof. Diamant Thaçi

13:45

Simplifying the journey: practical considerations
in modern AD management

Dr. Constanza Riquelme

13:55

Q&A and closing

Dr. Christine Bangert

Prof. Diamant Thaçi
Dr. Constanza Riquelme

Why attend

Join us to explore the many faces of atopic dermatitis and the challenges that matter in everyday practice – from the visible burden of face and neck involvement to the importance of achieving long-term sustained response across body regions. Discover emerging clinical evidence, gain insights into the new innovative evidence being generated on the difficult-to-treat regions of face and neck, and hear expert perspectives on practical approaches to simplifying modern AD management with lebrikizumab.

AD, atopic dermatitis
▼ EBGLYSS® is approved by EMA and authorised for commercialisation in a number of key markets including Germany, Spain and the United Kingdom. Access EBGLYSS® full SmPC clicking here. Click here for lebrikizumab SmPC. UK and Irish healthcare professionals, click here for UK/IE prescribing information and adverse event reporting instructions. These sessions are organized and funded by Almirall S.A. Almirall product will be discussed. Almirall event, booth and website are intended for healthcare professionals registered at the Congress.

Almirall’s faculty at EADV Congress 2026

Prof. Matthias Augustin

Redefining treatment success in psoriasis: moving beyond PASI to sustained disease control

Thursday, 1 October 2026

From 17:45 to 18:45 CEST

Dr. Christine Bangert

The many faces of AD – spotlight on visible burden, deep response, and simplicity in everyday care with lebrikizumab

Friday, 2 October 2026

From 13:00 to 14:00 CEST

Prof. Paolo 
Gisondi

Redefining treatment success in psoriasis: moving beyond PASI to sustained disease control

Thursday, 1 October 2026

From 17:45 to 18:45 CEST

Assoc. Prof. Marie Jachiet

Looking into the face of AD: tackling clinical cases in moderate-to-severe atopic dermatitis with face and neck involvement including lebrikizumab

Thursday, 1 October 2026

From 9:15 to 10:00 CEST

Prof. Anna López-Ferrer

Redefining treatment success in psoriasis: moving beyond PASI to sustained disease control

Thursday, 1 October 2026

From 17:45 to 18:45 CEST

Prof. Ulrich Mrowietz

Redefining treatment success in psoriasis: moving beyond PASI to sustained disease control

Thursday, 1 October 2026

From 17:45 to 18:45 CEST

Dr. Constanza Riquelme

The many faces of AD – spotlight on visible burden, deep response, and simplicity in everyday care with lebrikizumab

Friday, 2 October 2026

From 13:00 to 14:00 CEST

Prof. Diamant Thaçi

The many faces of AD – spotlight on visible burden, deep response, and simplicity in everyday care with lebrikizumab

Friday, 2 October 2026

From 13:00 to 14:00 CEST

Prof. Christian Vestergaard

Looking into the face of AD: tackling clinical cases in moderate-to-severe atopic dermatitis with face and neck involvement including lebrikizumab

Thursday, 1 October 2026

From 9:15 to 10:00 CEST

Any questions?

Contact us if you need more information related to Almirall portfolio.

Prof. Dr. Marjolein de Bruin-Weller

Utrech, The Netherlands

Satellite Symposium on atopic dermatitis

Precision in AD: how lebrikizumab is changing the treatment paradigm

Friday, Sept. 27th 2024 From 13:00 to 14:00 CEST

Biography

Marjolein de Bruin-Weller is full Professor and head of the National Expertise Center of Atopic Dermatitis, situated in the dpt. of Dermatology and Allergology of the University Medical Center Utrecht, The Netherlands.

Her major interest is clinical and translational research in atopic dermatitis. She is the principal investigator in several clinical trials and investigator-initiated studies focused on difficult to treat atopic dermatitis and systemic immunosuppressive and immuno-modulating treatment.

In 2018 she initiated the BioDay Registry in the Netherlands together with dr. Marie-Louise Schuttelaar from the department of Dermatology of the University Medical Center of Groningen. This registry is focused on the new advanced systemic treatments in atopic dermatitis and includes a lot of data regarding atopic dermatitis (signs, symptoms, quality of life, work impairment) as well as data on atopic co-morbidities. Currently 1900 patients from 18 sites in the Netherlands are included in the BioDay registry.

Together with Femke van Wijk, professor of tissue immunology at the Center of Translational Immunology (CTI) of the University Medical Center Utrecht, she leads the translational Atopic Dermatitis research group.

Marjolein de Bruin-Weller is chair of the Expertise group Allergy and Eczema of the Dutch Society of Dermatology and Venereology and member of the European Task Force of Atopic Dermatitis (ETFAD), the International Eczema Council (IEC) and the GA’LEN ADCARE Task Force. She is chair of the advisory board of the Dutch Patient Society for Atopic Dermatitis (VMCE) and member/chair of several Dutch committees regarding advanced systemic treatments in inflammatory diseases.

Dr. Andrew Blauvelt

Lake Oswego, United States

Satellite Symposium on atopic dermatitis

Precision in AD: how lebrikizumab is changing the treatment paradigm

Friday, Sept. 27th 2024 From 13:00 to 14:00 CEST

Biography

Dr. Blauvelt is a Consultant at Blauvelt Consulting, LLC. He received his undergraduate degree in electrical engineering at Purdue University, his medical degree at Michigan State University, and a healthcare MBA at Oregon Health & Science University (OHSU). Dr. Blauvelt trained in dermatology at the University of Miami and in cellular immunology under the direction of Dr. Steve Katz at the National Institutes of Health (NIH). Earlier in his career, he held senior staff positions at the NIH (Senior Investigator), OHSU (Professor), and the Portland VA Medical Center (Chief) as well as being Owner and President of Oregon Medical Research Center (OMRC) from 2013-2022. Dr. Blauvelt’s research and clinical expertise has been in Langerhans cell biology, T cell immunology, virology, psoriasis, and atopic dermatitis. He has published over 375 papers and spoken across the country and world on these topics. Within psoriasis research, his laboratory published key papers on the role of IL-23/Th17 biology in this disease. In recent years while at OMRC, he has been the international lead/senior investigator on a number of important clinical trials, including PSTELLAR, FEATURE, CLEAR, IXORA-R, VOYAGE 1, ECLIPSE, IMMhance, ABLE 1, BE ABLE 2, BE READY, BE RADIANT, OASIS-1, POETYK PSO-1, CHRONOS, ECZTEND, JADE REGIMEN, HEADS UP, ADhere, STRATUM, and KNOCKOUT. Dr. Blauvelt is also an elected member of the American Society for Clinical Investigation, the International Psoriasis Council, and the International Eczema Council. In 2023, he became Chair of the Medical Board for the National Psoriasis Foundation, an organization he has worked closely with for over 20 years in a variety of capacities. For the past 3 years, Dr. Blauvelt made the lists of Highly Cited Researchers, representing the top 1% of cited scientists in the world. 

Prof. Dr. Sascha Gerdes

Kiel, Germany

Satellite Symposium on atopic dermatitis

Precision in AD: how lebrikizumab is changing the treatment paradigm

Friday, Sept. 27th 2024 From 13:00 to 14:00 CEST

Biography

Department of Dermatology, Venereology, and Allergology, Center for Inflammatory Skin Diseases, University Medical Center

Schleswig-Holstein Campus Kiel, Kiel, Germany.

Sascha Gerdes is Professor of Dermatology, Venereology, Allergology and Immunology in the Department of Dermatology, Venereology, and Allergology at the Center for Inflammatory Skin Diseases, University Medical Center Schleswig-Holstein in Kiel, Germany. Since 2012, he has also been Head of the Department for Clinical Trials at the Center. Dr Gerdes earned his degree in medicine at the Christian-Albrechts University of Kiel Medical School in Kiel in 2004 and his MD degree in 2006 as well as his Habilitation in 2015 at the Institute of Human Genetics of the Christian-Albrechts University of Kiel and at the Department of Dermatology, Venereology and Allergology.

Dr Gerdes’ major research interests include inflammatory skin diseases and autoimmune dermatoses with a special interest in psoriasis. He has served as Sub-Investigator and Principal Investigator in multiple international, multicentre clinical trials in patients with moderate-to-severe plaque-type psoriasis, atopic dermatitis, scalp psoriasis, herpes simplex, and autoimmune dermatoses. He has earned a number of awards, including the Wyeth BioPharma Research Promotion Dermatology 2008, the AbbVie Research Award Dermatology 2013, and the German Psoriasis Award 2014 – a Research Award of the German Dermatological Society (DDG) – and is a member of the Scientific Advisory Board of the German Psoriasis Association and a member of the DDG, the ADF (Arbeitsgemeinschaft Dermatologische Forschung), and the BVDD (Professional Association of German Dermatologists). To date, Dr Gerdes has 130 published peer-reviewed articles referenced in the Medline database.

Prof. Jo Lambert

Ghent, Belgium

Satellite Symposium on psoriasis

Psoriasis: Is There Anything Left to Solve?

Thursday, September 18th / From 17:45 h. to 18:45 h. CEST
Satellite Symposium on psoriasis

Psoriasis: Is There Anything Left to Solve?

Thursday, September 18th
From 17:45 h. to 18:45 h. CEST

Biography

Prof. Jo Lambert is a Senior Full Professor in Dermatology and Venereology, and Chair of the Department of Dermatology at Ghent University, Ghent, Belgium. She is a specialist in immune dermatoses and pigment cell research.

Her research interests lie in the improvement of care in immune-mediated inflammatory skin disorders, ranging from advanced models of topical drug delivery to personalised dosing of biologicals. Prof. Lambert has 288 publications, 6,522 citations, and an H-index of 45. Additionally, she founded the DermPlus approach, an example of a value-based integrated practice unit for immune-mediated chronic skin diseases.

Currently, she is the chair of the European Academy of Dermatology and Venereology (EADV) Task Force Psoriasis, EADV Scientific Programming Committee member, and Councilor of the International Psoriasis Council. She is also a member of the Belgian Royal Academy of Medicine and European Dermatology Forum. In the 2010s, she served as Associate Editor and Editorial Assistant for the psoriasis and pigmentation section of the Journal of Investigative Dermatology, and she is now the Associate Editor of the Journal of European Academy Dermatology Venereology.

 

 

Prof. Andreas Pinter

Germany

Satellite Symposium on psoriasis

Psoriasis: Is There Anything Left to Solve?

Thursday, September 18th / From 17:45 h. to 18:45 h. CEST
Satellite Symposium on psoriasis

Psoriasis: Is There Anything Left to Solve?

Thursday, September 18th
From 17:45 h. to 18:45 h. CEST

Biography

Prof Andreas Pinter is a senior consultant dermatologist and Head of Clinical Research at the Clinic for Dermatology, Venereology and Allergology at the University Clinic in Frankfurt am Main, where he has also led the consultation service for chronic immune-mediated skin diseases since 2013. His clinical and scientific interests include chronic inflammatory dermatoses, dermato-oncology and dermatosurgery.

Since 2017, Prof Pinter has led a translational medicine working group that has secured independent, competitive research funding. This group focuses on elucidating the links between pathophysiological processes in hidradenitis suppurativa, atopic dermatitis and psoriasis, and their clinical burden. Prof Pinter is a frequent scientific speaker and the author or co-author of numerous publications in leading journals, including Nature, The Lancet, The New England Journal of Medicine (NEJM), JAMA Dermatology, the Journal of the American Academy of Dermatology (JAAD) and the British Journal of Dermatology (BJD).

He is actively involved in several national and international organisations in both membership and leadership roles, including the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the International Psoriasis Council (IPC) and various national networks.

Dr. Pedro Mendes Bastos

Portugal

Satellite Symposium on psoriasis

Psoriasis: Is There Anything Left to Solve?

Thursday, September 18th / From 17:45 h. to 18:45 h. CEST
Satellite Symposium on psoriasis

Psoriasis: Is There Anything Left to Solve?

Thursday, September 18th
From 17:45 h. to 18:45 h. CEST

Biography

Dr. Pedro Mendes Bastos is a Dermatology and Venerology Consultant at Hospital CUF Descobertas, Lisbon, Portugal. He is a highly respected specialist dedicated to immune-mediated diseases in Dermatology, including psoriasis, hidradenitis suppurativa, and atopic dermatitis.

He has been the Principal Investigator in numerous multicenter clinical trials in
immune-mediated skin diseases. Dr. Mendes Bastos has published numerous articles in highly respected journals, where his research articles have been cited over 1,700 times and he has a H-index of 19. Additionally, he frequently presents his clinical research at international and national conferences. Dr. Mendes Bastos has also played an incremental role in encouraging the implementation of multidisciplinary dermatology-rheumatology clinics for the treatment of psoriasis in Portugal.

Dr. Mendes Bastos is currently representing Portugal as a Board Member of European Academy of Dermatology and Venereology (EADV). He is a member of the Portuguese Psoriasis Group and also of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). He was the recipient of EADV’s John Stratigos Merit Award and has also won multiple awards and training scholarships from the Portuguese Society of Dermatology and Venereology.

 

Prof. Sébastien Barbarot

France

Satellite Symposium on atopic dermatitis

Long-term Control in Atopic Dermatitis: Elevating Therapeutic Goals

Thursday, September 19th / From 13:00 h. to 14:00 h. CEST
Satellite Symposium on atopic dermatitis

Long-term Control in Atopic Dermatitis: Elevating Therapeutic Goals

Thursday, September 19th
From 13:00 h. to 14:00 h. CEST

Biography

Prof. Sébastien Barbarot is Professor and Head of Dermatology at the University Hospital of Nantes, France. He also leads the Dermatology Clinical Trial Unit and the Paediatric Dermatology Unit at Nantes University Hospital.

His research focuses on atopic dermatitis, with particular expertise in prevention strategies and therapeutic patient education. He leads several academic clinical trials, including antenatal interventions to prevent atopic dermatitis, and has been involved in numerous academic and pharmaceutical clinical trials across dermatological conditions. Prof. Barbarot has authored more than 340 peer-reviewed publications and has an h-index of 58.

He has received substantial research funding for academic randomized clinical trials and translational projects on atopic dermatitis. Prof. Barbarot is Chair of the French Atopic Dermatitis Network (FRADEN), founding member and Co-Chair of the Groupe de Recherche sur l’Eczéma Atopique (GREAT), and former Chair of the French Society of Paediatric Dermatology. He served as Vice-Chair of the European Task Force on Atopic Dermatitis from 2016 to 2024 and is a member of the HOME initiative and the international TREAT Registry Task Force.

Prof. Tilo Biedermann

Germany

Satellite Symposium on atopic dermatitis

Long-term Control in Atopic Dermatitis: Elevating Therapeutic Goals

Thursday, September 19th / From 13:00 h. to 14:00 h. CEST
Satellite Symposium on atopic dermatitis

Long-term Control in Atopic Dermatitis: Elevating Therapeutic Goals

Thursday, September 19th
From 13:00 h. to 14:00 h. CEST

Biography

Prof. Tilo Biedermann is Professor and Chair of the Department of Dermatology and Allergology at the Technical University of Munich. He is also the Deputy Medical Director of the University of Hospital, Technical University of Munich.

His research primarily focuses on the immunopathogenesis of atopic dermatitis and psoriasis, with a particular emphasis on skin barrier dysfunction. Prof. Biedermann has published over
400 articles in highly respected journals and has a h-index of 59.

He has won numerous awards for his contributions both to teaching and research in dermatology, including the Bavarian State’s Ministry of Science and the Arts for excellent teaching and the International Alfred Marchionini Research Award. Prof. Biedermann is also highly active member of the dermatology community, such as being the former President of the German Society of Dermatology and of the European Society of Dermatologic Research.

Prof. Richard Warren

United Kingdom

Satellite Symposium on atopic dermatitis

Long-term Control in Atopic Dermatitis: Elevating Therapeutic Goals

Thursday, September 19th / From 13:00 h. to 14:00 h. CEST
Satellite Symposium on atopic dermatitis

Long-term Control in Atopic Dermatitis: Elevating Therapeutic Goals

Thursday, September 19th
From 13:00 h. to 14:00 h. CEST

Biography

Professor Richard Warren is a consultant dermatologist in Manchester, United Kingdom. He graduated from Liverpool University with a first-class honours degree in Pharmacology and gained his medical degree with honours one year later. His work in dermatology has focused on pharmacogenetics, the genetic susceptibility to psoriasis and biologic therapies in the treatment of psoriasis for which he has received national and international awards. His roles include Head of Centre for Dermatology at the University of Manchester, immediate past Academic Vice President of the British Association of Dermatologists and Lead for Early Phase trial research across the Northern Care Alliance in Greater Manchester. Professor Warren is the chief investigator of British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) one of the largest drug safety registries in dermatology worldwide. He has published widely in the field of dermatology with >300 papers including 1st author original articles in The Lancet and New England Journal of Medicine.

Dr. Alessandra Narcisi

Italy

Satellite Symposium on atopic dermatitis

Long-term Control in Atopic Dermatitis: Elevating Therapeutic Goals

Thursday, September 19th / From 13:00 h. to 14:00 h. CEST
Satellite Symposium on atopic dermatitis

Long-term Control in Atopic Dermatitis: Elevating Therapeutic Goals

Thursday, September 19th
From 13:00 h. to 14:00 h. CEST

Biography

Dr. Alessandra Narcisi is a Researcher and Adjunct Professor of Dermatology at both the Humanitas University of Milan and at the School of Medicine at the University of Humanitas, Milan. She holds a PhD in innovative surgical technologies of the skin, skeleton, and craniofacial regions.

Her research is primarily focused on the use of biologics in the treatment of atopic dermatitis and psoriasis. She has published over 200 peer-reviewed articles and has presented her research findings at both national and international journals. Additionally, she has been the Principal Investigator for numerous European clinical trials and was also a member of a large epidemiological study on the diagnosis and treatment of skin diseases.

 

Welcome to almiralldermatologycongress.com

The information provided on this website is intended for use by healthcare professionals qualified to prescribe and supply medications, thus requiring specific scientific knowledge and training to interpret it correctly.

I'm not a Healthcare Professional

I'm a Healthcare Professional

Leaving almiralldermatologycongress.com

Dear User,

You are about to leave almiralldermatologycongress.com since your request does not correspond to Almirall’s content related to EADV Congress 2024.

We will redirect you to almirall.com

Thanks for your visit.

Come back soon!

Prof. Dirschka

Germany

Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST
Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST

Biography

Thomas Dirschka graduated in medicine at the University of Bochum, Germany in 1993 and has since specialised in dermatology. After a period of research at the Medical College of Virginia in the USA, Professor Dirschka returned to Germany and did further research work before entering private dermatological practice.

His areas of special interest include prevention and treatment of skin cancer, inflammatory skin diseases, allergy,dermatopathology, and aesthetic dermatology.

He is actively involved in clinical study programmes and clinical trials to determine the efficacy and safety of novel treatments for dermatological conditions. In 2000 Professor Dirschka founded CentroDerm®, a company for research and development in the field of dermatology. In this context he runs a skin physiology laboratory for investigation of skin barrier function, skin sensitivity and effects of topical applications on the skin.

Prof. Fargnoli

Italy

Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST
Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST

Biography

Maria Concetta Fargnoli is Full Professor of Dermatology and Chair of the Department of Dermatology at the University of L’Aquila, Italy. She received her medical degree in 1992 at the University of Rome “Tor Vergata”, completed her residency in Dermatology and Venereology at the University of L’Aquila in 1998 and started her academic career in 1999. She is the Director of the Laboratory of Molecular Biology in Dermato-Oncology, Director of the Interdepartmental Centre of Molecular Diagnostics and Advanced Therapies, Faculty of the PhD Program in Experimental Medicine at the University of L’Aquila and Coordinator of the Skin Cancer Tumor Board.

Her clinical and experimental research interests include epidemiology and molecular genetics of melanoma and non-melanoma skin cancers, non-invasive diagnostic techniques in dermatology, new therapeutic interventions for inflammatory and neoplastic skin diseases. She is actively involved in conducting clinical trials primarily focusing on non-melanoma skin cancers, psoriasis, atopic dermatitis and prurigo nodularis.

She has published 265 peer-reviewed scientific papers, contributed to many book chapters and lectured at national and international meetings. Prof. Fargnoli acts as reviewer of international journals on dermatology, oncology and genetics.

Prof. Fargnoli is currently VicePresident of the Italian Society of Dermatology (SIDeMaST) and has been board member, secretary, coordinator of the Group of Experimental Research and Bioengeneering in Dermatology and coordinator of the Scientific Committee of SIDeMaST.

Dr. Boada

Spain

Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST
Almirall Satellite Symposium

Doctor, is it cancer? Main AK patients' concerns and therapeutic approaches

21st April 2023 / From 15:00 h to 15:45 h CEST

Biography

Dr. Aram Boada (Barcelona, 1979) is a specialist in Dermatology and Venereology (2008) and PhD degree from the Universitat Autònoma de Barcelona (2020). He works as Section Chief and Melanoma Unit Coordinator of the Dermatology Department of Hospital Universitari Germans Trias i Pujol in Badalona (Barcelona, Spain). His main fields of research are Dermato-Oncology (melanoma, field cancerization and cutaneous toxicities of oncologic treatments) with more than 100 publications and conference communications.